- Home
- UWMC vs AUPH Comparison
UWMC vs AUPH Comparison
Compare UWMC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- AUPH
- Stock Information
- Founded
- UWMC 1986
- AUPH 1993
- Country
- UWMC United States
- AUPH Canada
- Employees
- UWMC N/A
- AUPH N/A
- Industry
- UWMC Finance: Consumer Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- AUPH Health Care
- Exchange
- UWMC Nasdaq
- AUPH Nasdaq
- Market Cap
- UWMC 1.4B
- AUPH 1.4B
- IPO Year
- UWMC N/A
- AUPH 1999
- Fundamental
- Price
- UWMC $6.87
- AUPH $12.57
- Analyst Decision
- UWMC Hold
- AUPH Strong Buy
- Analyst Count
- UWMC 7
- AUPH 4
- Target Price
- UWMC $5.54
- AUPH $12.25
- AVG Volume (30 Days)
- UWMC 8.9M
- AUPH 1.7M
- Earning Date
- UWMC 11-06-2025
- AUPH 11-06-2025
- Dividend Yield
- UWMC 5.79%
- AUPH N/A
- EPS Growth
- UWMC 112.84
- AUPH N/A
- EPS
- UWMC 0.07
- AUPH 0.42
- Revenue
- UWMC $2,622,828,000.00
- AUPH $260,111,000.00
- Revenue This Year
- UWMC $25.96
- AUPH $16.92
- Revenue Next Year
- UWMC N/A
- AUPH $14.29
- P/E Ratio
- UWMC $104.25
- AUPH $30.38
- Revenue Growth
- UWMC 13.45
- AUPH 25.59
- 52 Week Low
- UWMC $3.80
- AUPH $6.42
- 52 Week High
- UWMC $9.25
- AUPH $12.82
- Technical
- Relative Strength Index (RSI)
- UWMC 78.62
- AUPH 64.23
- Support Level
- UWMC $5.50
- AUPH $12.06
- Resistance Level
- UWMC $7.14
- AUPH $12.82
- Average True Range (ATR)
- UWMC 0.22
- AUPH 0.37
- MACD
- UWMC 0.09
- AUPH -0.06
- Stochastic Oscillator
- UWMC 88.25
- AUPH 77.31
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.